secwatch / observer
8-K filed March 11, 2026, 7:59 PM ET ticker WGRX CIK 0002030763
other material confidence high sentiment positive materiality 0.50

Wellgistics Health secures preferred EBV pricing via Kare PharmTech revenue-share deal

Wellgistics Health, Inc.

item 1.01item 7.01item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001493152-26-009702
form_type
8-K
ticker
WGRX
cik
0002030763
company_name
Wellgistics Health, Inc.
filed_at
2026-03-11T23:59:59+00:00
discovered_at
2026-05-14T18:02:37.050407+00:00
generated_at
2026-05-15T15:13:31.463703+00:00
sec_items
["1.01", "7.01", "9.01"]
event_type
other_material
sentiment
positive
materiality_score
0.5
calibrated_materiality_score
0.5
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001493152-26-009702
json_url
https://secwatch.observer/filing/0001493152-26-009702.json
markdown_url
https://secwatch.observer/filing/0001493152-26-009702.md
text_url
https://secwatch.observer/filing/0001493152-26-009702.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/2030763/000149315226009702/0001493152-26-009702-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/2030763/000149315226009702/form8-k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

c7b0deac2d209b04a119f4a7bc74f9448c394286

Wellgistics Health, Inc. entered into Interim Commercialization and Revenue Share Agreement with Kare PharmTech LLC (effective 2026-03-06).

On March 6, 2026, Wellgistics Health, Inc. (the “Company”), entered into an Interim Commercialization and Revenue Share Agreement (the “Revenue Share Agreement”) with Kare PharmTech LLC

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

Comparable filings

VTIX

Virtuix amends warrants to $4.00 exercise price, extends period to July 27, 2026

Virtuix Holdings Inc. June 2, 2026, 9:15 AM ET other_material Items 1.01, 7.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 7.01, 9.01 same event type: other_material similar materiality

This filing

On March 6, 2026, Wellgistics Health, Inc. (the “Company”), entered into an Interim Commercialization and Revenue Share Agreement (the “Revenue Share Agreement”) with Kare PharmTech LLC

Comparable filing

On June 1, 2026, Virtuix Holdings Inc. (the “Company”) entered into amendments to each of the following warrants to purchase shares of Class A Common Stock (collectively, the “Warrant Amendments”) with Streeterville Capital, LLC (the “Investor”) amending the exercise price and extending the Reduced Exercise Price Period (as defined below) to each such warrant

Filing page SEC filing

BJDX

Bluejay Diagnostics partners with Argonaut for US-based Symphony platform manufacturing

Bluejay Diagnostics, Inc. June 2, 2026, 6:30 AM ET other_material Items 1.01, 7.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 7.01, 9.01 same event type: other_material similar materiality

This filing

On March 6, 2026, Wellgistics Health, Inc. (the “Company”), entered into an Interim Commercialization and Revenue Share Agreement (the “Revenue Share Agreement”) with Kare PharmTech LLC

Comparable filing

On May 27, 2026, Bluejay Diagnostics, Inc. (the “Company”) entered into an agreement and statement of work (together, the “Agreement”) with Argonaut Manufacturing Services c/o Argonaut, Inc. (“Argonaut”) regarding the provision by Argonaut to the Company of certain manufacturing services to support the Company’s SymphonyTM platform.

Filing page SEC filing

LTRX

Lantronix prices $30M common stock offering at $7.20/share; net proceeds ~$32.3M

LANTRONIX INC June 1, 2026, 4:15 PM ET other_material Items 1.01, 7.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 7.01, 9.01 same event type: other_material similar materiality

This filing

On March 6, 2026, Wellgistics Health, Inc. (the “Company”), entered into an Interim Commercialization and Revenue Share Agreement (the “Revenue Share Agreement”) with Kare PharmTech LLC

Comparable filing

On May 29, 2026, Lantronix, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Needham & Company, LLC and Canaccord Genuity LLC, as underwriters (together, the “Underwriters”), pursuant to which the Company agreed to sell, and the Underwriters agreed to purchase, 4,166,667 shares (the “Firm Shares”) of the Company’s common stock

Filing page SEC filing

BNAI

BEN invests $1M in Accelevate, signs exclusive Mexico reseller and global deal

Brand Engagement Network Inc. May 11, 2026, 7:59 PM ET other_material Items 1.01, 7.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 7.01, 9.01 same event type: other_material similar materiality

This filing

On March 6, 2026, Wellgistics Health, Inc. (the “Company”), entered into an Interim Commercialization and Revenue Share Agreement (the “Revenue Share Agreement”) with Kare PharmTech LLC

Comparable filing

On May 7, 2026, following the successful completion of due diligence, entered into two definitive Reseller Agreements (the “Commercial Agreements”) with Accelevate.

Filing page SEC filing

MEDICAL EXERCISE INC.

Medical Exercise signs first franchise agreement for Canadian OnCore Longevity Center

MEDICAL EXERCISE INC. May 8, 2026, 7:59 PM ET other_material Items 1.01, 7.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 7.01, 9.01 same event type: other_material similar materiality

This filing

On March 6, 2026, Wellgistics Health, Inc. (the “Company”), entered into an Interim Commercialization and Revenue Share Agreement (the “Revenue Share Agreement”) with Kare PharmTech LLC

Comparable filing

On May 6, 2026, Medical Exercise Inc. (the “Company”) entered into a Franchise Agreement (the “Agreement”) with Degco Fitness Ventures Ltd., a corporation based in Regina, Saskatchewan, Canada.

Filing page SEC filing

XWIN

XMax raises $3.6M via private placement of 486,500 shares at $7.347/share

XMax Inc. June 2, 2026, 4:30 PM ET other_material Items 1.01, 3.02, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

On March 6, 2026, Wellgistics Health, Inc. (the “Company”), entered into an Interim Commercialization and Revenue Share Agreement (the “Revenue Share Agreement”) with Kare PharmTech LLC

Comparable filing

On May 28, 2026, XMax Inc. (the “ Company ”) entered into Securities Purchase Agreements (the “ Agreements ”) with certain non-U.S. investors identified on the signature pages thereto (the “ Purchasers ”), pursuant to which the Company agreed to sell to the Purchasers in a private placement for a total of 486,500 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a purchase price of $7.347 per share for an aggregate offering price of $3,574,315.50 (the “ Private Placement ”).

Filing page SEC filing

JAGX

Jaguar Health issues 64,668 common shares for Series Q Preferred; annual meeting adjourned to June 8

Jaguar Health, Inc. June 2, 2026, 4:10 PM ET other_material Items 1.01, 3.02, 8.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

On March 6, 2026, Wellgistics Health, Inc. (the “Company”), entered into an Interim Commercialization and Revenue Share Agreement (the “Revenue Share Agreement”) with Kare PharmTech LLC

Comparable filing

On May 26, 2026, the Company entered into a privately negotiated exchange agreement with Streeterville (the “First Exchange Agreement”), pursuant to which the Company issued 31,958 shares (the “First Exchange Shares”) of the Company’s common stock, par value $0.0001 (the “Common Stock”) to Streeterville in exchange for an aggregate of 3.72 outstanding shares of Series Q Preferred Stock held by Streeterville (the “First Exchanged Preferred Shares”).

Filing page SEC filing

CURB

Curbline Properties enters up to $400M ATM equity offering; prior program terminated

Curbline Properties Corp. June 2, 2026, 8:07 AM ET other_material Items 1.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

On March 6, 2026, Wellgistics Health, Inc. (the “Company”), entered into an Interim Commercialization and Revenue Share Agreement (the “Revenue Share Agreement”) with Kare PharmTech LLC

Comparable filing

On June 2, 2026, Curbline Properties Corp. (the “ Company ”) and Curbline Properties LP (the “ Operating Partnership ”) entered into an ATM Equity Offering Sales Agreement (the “ Equity Sales Agreement ”) with Jefferies LLC, BNY Mellon Capital Markets, LLC, BofA Securities, Inc., BTIG, LLC, Capital One Securities, Inc., Goldman Sachs & Co. LLC, KeyBanc Capital Markets Inc., Morgan Stanley & Co. LLC, Nomura Securities International, Inc., StoneX Financial Inc. and Wells Fargo Securities, LLC, as sales agents

Filing page SEC filing

Source: SEC EDGAR
accession 0001493152-26-009702
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.